Assignee
SIGNAL PHARM LLC
US·103 granted patents·25 pending applications·952 citations·filing 1998–2024
Top patents by PatentIndex Score
128 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0297US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0397US9365524B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2015·Granted Jun 14, 2016·22 cites·36 claims
- 0496US9814713B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2016·Granted Nov 14, 2017·14 cites·21 claims
- 0596US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0696US9701643B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Jul 11, 2017·19 cites·18 claims
- 0795US8383634B2Methods of treatment using heteroaryl compounds and compositions thereofSIGNAL PHARM LLC·Filed 2011·Granted Feb 26, 2013·46 cites·4 claims
- 0895US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0995US7968556B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jun 28, 2011·41 cites·3 claims
- 1095US7723340B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2006·Granted May 25, 2010·46 cites·51 claims
- 1194US10040770B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Aug 7, 2018·7 cites·18 claims
- 1294US7521446B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2006·Granted Apr 21, 2009·39 cites·60 claims
- 1393US10266500B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Apr 23, 2019·5 cites·14 claims
- 1493US9187479B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Nov 17, 2015·17 cites·12 claims
- 1593US7759342B2Methods of treatment and prevention using haloaryl substituted aminopurinesSIGNAL PHARM LLC·Filed 2007·Granted Jul 20, 2010·35 cites·7 claims
- 1693US7129242B2Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2001·Granted Oct 31, 2006·59 cites·2 claims
- 1792US11325890B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted May 10, 2022·2 cites·18 claims
- 1892US9725450B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Aug 8, 2017·9 cites·9 claims
- 1992US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 2092US9359364B2Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-oneSIGNAL PHARM LLC·Filed 2014·Granted Jun 7, 2016·10 cites·28 claims
- 2191US9796685B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2015·Granted Oct 24, 2017·14 cites·7 claims
- 2290US10004735B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2017·Granted Jun 26, 2018·4 cites·16 claims
- 2390US9737535B2Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazinesSIGNAL PHARM LLC·Filed 2015·Granted Aug 22, 2017·5 cites·16 claims
- 2490US9474757B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Oct 25, 2016·16 cites·20 claims
- 2590US9155736B2Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activitySIGNAL PHARM LLC·Filed 2013·Granted Oct 13, 2015·16 cites·6 claims
- 2689US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 2789US9505764B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Nov 29, 2016·11 cites·33 claims
- 2889US9358232B2Methods for treating cancer using TOR kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2014·Granted Jun 7, 2016·13 cites·6 claims
- 2988US10398700B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 3088US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 3188US9513297B2Methods for measurement of inhibition of c-Jun N-terminal kinase in skinSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·14 cites·6 claims
- 3288US9403829B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2012·Granted Aug 2, 2016·13 cites·29 claims
- 3388US9375443B2Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinibSIGNAL PHARM LLC·Filed 2013·Granted Jun 28, 2016·12 cites·4 claims
- 3488US9198866B2Pharmaceutical formulations of a substituted diaminopurineSIGNAL PHARM LLC·Filed 2013·Granted Dec 1, 2015·15 cites·18 claims
- 3588US7354947B2Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Apr 8, 2008·10 cites·4 claims
- 3688US2025000860A1Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2024·Application pending·0 cites
- 3787US10149849B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Dec 11, 2018·2 cites·3 claims
- 3886US10919865B2Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted Feb 16, 2021·3 cites·16 claims
- 3986US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 4086US7442699B2Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2005·Granted Oct 28, 2008·10 cites·8 claims
- 4186US7220771B2Methods of using indazole derivatives as JNK inhibitorsSIGNAL PHARM LLC·Filed 2003·Granted May 22, 2007·22 cites·4 claims
- 4285US10975039B2Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2020·Granted Apr 13, 2021·1 cites·7 claims
- 4385US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 4485US8686135B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2013·Granted Apr 1, 2014·8 cites·21 claims
- 4585US6987184B2Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods relatedSIGNAL PHARM LLC·Filed 2002·Granted Jan 17, 2006·19 cites·4 claims
- 4684US10689351B2Isotopologues of 2-(tert butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2019·Granted Jun 23, 2020·1 cites·7 claims
- 4784US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 4884US10131639B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2017·Granted Nov 20, 2018·4 cites·18 claims
- 4984US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 5084US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
Showing the top 50 of 128 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SIGNAL PHARM LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →